Patents by Inventor Nobutaka Fujii
Nobutaka Fujii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9034814Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.Type: GrantFiled: May 21, 2006Date of Patent: May 19, 2015Assignees: Hadasit Medical Research Services and Development Ltd., Kyoto UniversityInventors: Amnon Peled, Nobutaka Fujii
-
Patent number: 8772297Abstract: The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-?-related diseases: wherein Y is a hydrogen atom and the like; R2 is and the like; R3 is —NR8—R9— and the like; R4, R5, R6 and R7 are the same or different and each is a hydrogen atom and the like; and X is and the like.Type: GrantFiled: February 17, 2011Date of Patent: July 8, 2014Assignee: Kyoto UniversityInventors: Hideaki Kakeya, Akira Hattori, Yasuaki Takasu, Nobutaka Fujii, Shinya Oishi, Soichi Kojima, Mitsuko Hara
-
Patent number: 8592379Abstract: The present invention provides a metastin derivative represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition containing it. The metastin derivative or a salt thereof is superior in blood stability, and has a cancer metastasis suppressive action or cancer growth suppressive action.Type: GrantFiled: April 28, 2009Date of Patent: November 26, 2013Assignees: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita
-
Patent number: 8435939Abstract: The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.Type: GrantFiled: August 25, 2009Date of Patent: May 7, 2013Assignee: Biokine Therapeutics Ltd.Inventor: Nobutaka Fujii
-
Patent number: 8410059Abstract: Therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt are described. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: GrantFiled: July 8, 2011Date of Patent: April 2, 2013Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Publication number: 20130045977Abstract: The present invention provides a compound represented by the following formula (I) or a physiologically acceptable salt thereof, and use thereof for the prophylaxis or treatment of TGF-?-related diseases: wherein Y is a hydrogen atom and the like; R2 is and the like; R3 is —NR8—R9— and the like; R4, R5, R6 and R7 are the same or different and each is a hydrogen atom and the like; and X is and the like.Type: ApplicationFiled: February 17, 2011Publication date: February 21, 2013Applicant: KYOTO UNIVERSITYInventors: Hideaki Kakeya, Akira Hattori, Yasuaki Takasu, Nobutaka Fujii, Shinya Oishi, Soichi Kojima, Mitsuko Hara
-
Patent number: 8183212Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.Type: GrantFiled: October 24, 2006Date of Patent: May 22, 2012Assignees: Kyoto University, Takeda Phamaceutical Company LimitedInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita, Ayumu Niida
-
Publication number: 20110269686Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: ApplicationFiled: July 8, 2011Publication date: November 3, 2011Applicant: BIOKINE THERAPEUTICS LTD.Inventors: Nobutaka FUJII, Hirokazu TAMAMURA, Akira HORI
-
Patent number: 8017585Abstract: Peptides, their amides, esters or salts, which have CXCR4 antagonistic action, have therapeutic effects for cancer and chronic rheumatoid arthritis.Type: GrantFiled: July 11, 2008Date of Patent: September 13, 2011Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Publication number: 20110039786Abstract: The present invention provides a metastin derivative represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition containing it. The metastin derivative or a salt thereof is superior in blood stability, and has a cancer metastasis suppressive action or cancer growth suppressive action.Type: ApplicationFiled: April 28, 2009Publication date: February 17, 2011Applicants: KYOTO UNIVERSITY, TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita
-
Publication number: 20110014649Abstract: The present invention relates to the production of an N36-binding peptide at low cost and in a large quantity utilizing a microorganism. More specifically, the present invention relates to a method for producing an N36-binding peptide comprising introducing a recombinant vector into which a DNA molecule encoding an N36-binding peptide that binds to an N36 protein derived from a retrovirus that causes immunodeficiency in a mammal has been incorporated into E. coli as a host to produce a transformant.Type: ApplicationFiled: July 26, 2007Publication date: January 20, 2011Applicant: GEKKEIKAN SAKE CO., LTD.Inventors: Hiroko Tsutsumi, Hiroki Ishida, Hiromoto Hisada, Makiko Mizumoto, Yoji Hata, Nobutaka Fujii, Masao Matsuoka, Eiichi Kodama, Shinya Oishi
-
Publication number: 20100222256Abstract: The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.Type: ApplicationFiled: August 25, 2009Publication date: September 2, 2010Inventor: Nobutaka Fujii
-
Publication number: 20100160241Abstract: The present invention provides a compound represented by the following formula (1); wherein R1 is an aryl group etc.; R2 is —CO—NH— etc.; R3 is a methyl group having an aromatic group or a cycloalkyl group; R4 is a hydrogen atom etc.; R5 is a methyl group having an aromatic group; and R6 is an amino group or an N-alkyl substituted amino group, having a low-molecular weight and a superior GPR54 agonist activity, and a pharmaceutical composition containing the compound.Type: ApplicationFiled: October 24, 2006Publication date: June 24, 2010Applicant: Kyoto UniversityInventors: Nobutaka Fujii, Shinya Oishi, Kenji Tomita, Ayumu Niida
-
Publication number: 20100055088Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialisation in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.Type: ApplicationFiled: May 21, 2006Publication date: March 4, 2010Applicants: Hadasit Medical Research Services and Development Ltd., Kyoto UniversityInventors: Amnon Peled, Nobutaka Fujii
-
Patent number: 7595298Abstract: The present invention relates to a polypeptide represented by the formula: A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7??(I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.Type: GrantFiled: August 1, 2006Date of Patent: September 29, 2009Assignee: Biokine Therapeutics Ltd.Inventor: Nobutaka Fujii
-
Publication number: 20090181897Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: ApplicationFiled: July 11, 2008Publication date: July 16, 2009Applicant: BIOKINE THERAPEUTICS LTD.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Patent number: 7495011Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.Type: GrantFiled: July 14, 2004Date of Patent: February 24, 2009Assignee: aRigen Pharmaceuticals, Inc.Inventors: Nobutaka Fujii, Naoki Yamamoto
-
Publication number: 20090036416Abstract: A novel non-peptide CXCR4 antagonist has a low molecular-weight and uses various aromatic compounds, each containing a dipicolylamine-zinc complex. This CXCR4 antagonist finds use, e.g., as an anti-HIV agent, a metastasis inhibitor for a malignant tumor, and a chronic rheumatoid arthritis treatment and/or prevention agent.Type: ApplicationFiled: December 27, 2006Publication date: February 5, 2009Applicant: Kyoto UniversityInventors: Nobutaka Fujii, Itaru Hamachi, Akio Ojida, Hirokazu Tamamura, Hideki Nakashima
-
Patent number: 7423007Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: GrantFiled: August 26, 2003Date of Patent: September 9, 2008Assignee: Biokine Therapeutics Ltd.Inventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori
-
Publication number: 20060264378Abstract: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.Type: ApplicationFiled: August 26, 2003Publication date: November 23, 2006Applicant: Takeda Pharmaceutical Company LimitedInventors: Nobutaka Fujii, Hirokazu Tamamura, Akira Hori